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Abstract 
This article describes the development of a procedure for the simultaneous evaluation of 
the activity of six different UDP-glucuronyltransferases (UGT) in human liver 
microsomes (HLM). The method consists of incubations of probe substrates for UGT1A1 
(etoposide), UGT1A3 (chenodeoxycholic acid), UGT1A4 (trifluoperazine), UGT1A6 
(serotonin), UGT1A9 (mefenamic acid) and UGT2B7 (azidothymidine) with HLM. The 
six substrates were divided into three different incubations (etoposide + mefenamic acid; 
chenodeoxycholic acid + serotonin + azydothymidine, and trifluoperazine alone), the 
media of which were pooled before analysis. Glucuronide formation rates were 
determined in a single-run of 20 minutes using a validated liquid chromatography-tandem 
mass spectrometry method. No significant difference was observed between 
glucuronidation activities measured using the present procedure and individual 
incubations of the probes. The method was used successfully for the determination of 
UGT activities in 44 individual HLM preparations and for the phenotyping of 
preparations predicted to have altered UGT1A1 and UGT2B7 activities because of 
known genetic polymorphisms. 
 
Keywords: UDP-glucuronosyltransferase; microsomes; liquid chromatography; tandem 
mass spectrometry; drug metabolism 
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Introductory statement 
Glucuronidation is a major drug metabolic pathway, catalyzed by uridine diphosphate 
(UDP)-glucuronosyltranferases (UGT). Two main families of UGTs have been identified 
in humans, namely UGT1A and UGT2 (subdivided in UGT2A and UGT2B) [1, 2]. The 
UGT 1A family consists of 9 functionally active proteins: UGT 1A1, 1A3, 1A4, 1A6 and 
1A9, predominantly expressed in the liver, and UGT1A5, 1A7, 1A8 and 1A10 which are 
almost exclusively extrahepatic [3, 4]. The UGT2A (2A1, 2A2 and 2A3) enzymes are 
found mainly in olfactory tissues, although UGT2A3 might also be expressed in 
significant amount in the liver [5, 6]. The UGT2B subfamily comprises seven functional 
members (UGT2B4, 2B7, 2B10, 2B11, 2B15, 2B17, and 2B28) [3], with several 
expressed in the liver (UGT2B4, 2B7, 2B10, 2B15, and 2B17). 
Drug glucuronides are hydrophilic products which are excreted in the urine or bile [7]. 
They usually exhibit lower pharmacological activity, but in a number of cases they can be 
more active than the parent compound (e.g., morphine-6-glucuronide) [8] or highly 
reactive (e.g., acyl-glucuronides) [9]. In addition, drug glucuronidation exhibits 
substantial interindividual variability which can result in altered drug pharmacological 
profiles [10]. It thus becomes increasingly apparent that the study of drug glucuronidation 
has to be included in the process of enzyme reaction phenotyping during drug 
development, but this requires qualified biological systems (e.g., liver microsomes, 
hepatocytes) with known enzyme contents or activities. In this context, several authors 
have proposed UGT phenotyping assays. However, the assays are based on various 
analytical techniques and are usually dedicated to one particular isoform [5, 11-14]. Only 
Donato et al. reported a single liquid chromatography-tandem mass spectrometry (LC-
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MS/MS) method which can be applied to the activity measurements of four major human 
hepatic UGTs (1A1, 1A6, 1A9 and 2B7) [15]. 
The present work aimed at establishing a n-in one assay to phenotype six major human 
UGTs (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) in human liver microsomes (HLM), 
using incubations of selective substrates followed by a single LC-MS/MS determination 
of their glucuronides. The procedure allowed the description of hepatic glucuronidation 
interindividual variability in a bank of 44 HLM. 
 
Materials and Methods 
Chemicals and reagents 
Etoposide (ETO), chenodeoxycholic acid (CDCA), serotonin (SER), mefenamic acid 
(MEF), trifluoperazine (TFP), alamethicin, UDP-glucuronic acid (UDPGA), estradiol, 
dimethyl sulfoxide (DMSO) and glafenine (GLF) were obtained from Sigma-Aldrich (St 
Louis, MO). MgCl2 was purchased from Merck (Darmstadt, Germany) and Tris-HCl 
from Qbiogene (Solon, OH). Azidothymidine (AZT) was provided by GlaxoSmithKline 
(Nanterre, France). All reagents were of analytical grade. 
Enzymes and microsomes 
A pool of mixed men and women HLM as well as microsomes prepared from 
baculovirus-infected insect cells expressing the human UGT1A1, 1A3, 1A4, 1A6, 1A9, 
2B4, 2B7, 2B15 and 2B17 (Supersomes®), and a control preparation, were purchased 
from BD Biosciences Gentest (Woburn, MA). 
Human liver tissue samples derived from 44 surgical specimens were obtained from 
Biopredic International (Rennes, France). All samples were collected after singular 
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donors had given their informed consent, in accordance with the French bioethics laws. 
The genomic DNA of each liver sample had been previously extracted and genotyped for 
the UGT1A1 TA repeat (UGT1A1*28) and UGT2B7 -842G>A (rs7438135) 
polymorphisms as reported recently [16]. Genotype distributions were in Hardy-
Weinberg equilibrium. Individual human liver microsomes (HLM) were prepared as 
previously described [17]. Briefly, liver samples were homogenized in a 50 mM pH 8 
phosphate buffer containing 0.25 M saccharose, 10 mM EDTA and 0.1 mM dithiothreitol 
following a two-step disruption process using an Ultraturax homogenizer (IKA Werke, 
Staufen, Germany) and a Dounce homogenizer (Wheaton, Millvill, USA). The 
microsomal fraction was then obtained by differential centrifugation as described [17]. 
Microsomes were suspended in 0.1 mM phosphate buffer pH 8.0 containing 1 mM 
EDTA, 1 mM dithiothreitol and 20 % glycerol (v:v). The suspension was divided into 
aliquots and stored at –80°C. Protein concentration was measured according to the 
Bradford’s method using bovine serum albumin as standard. 
Assay incubation conditions and sample preparation 
All incubations were done under linear conditions with respect to time and protein 
concentration. The incubation buffer consisted of 0.1 M Tris-HCl (final pH=7.4) 
containing 10 mM MgCl2. Incubations contained either an individual substrate or a 
mixture of substrates (20 µL). Substrate stock solutions were prepared in DMSO at a 
120X concentration and stored at +4°C. Solutions at a 40X concentration were obtained 
by diluting stock solutions with DMSO (individual substrate), or with two or three other 
individual substrate stock solutions. The 40X solutions were then diluted to 1X solutions 
in the incubation buffer before each experiment. Microsomes were diluted in the 
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incubation buffer to a concentration of 2.5 mg/mL and then activated by incubation with 
an equal volume of alamethicin (0.25 mg/mL in incubation buffer) for 15 min on ice. 
Typical incubations (50 µL) contained: 20µL of activated microsomes (HLM or 
Supersomes; 0.5 mg/mL final concentration), 10µL of the co-substrate (UDPGA prepared 
in the incubation buffer; 2 mM final concentration), and 20µL of 1X substrate solutions 
(final concentrations given in Table 1). DMSO final concentration in incubation medium 
was 0.5% (v:v). 
Substrates and microsomes were pre-incubated for 5 min at 37°C in a shaking water bath 
and the reaction initiated by addition of the co-substrate. After 60 min at 37°C, reactions 
were quenched with 40 µL of ice cold methanol. Samples were vortex-mixed and 
centrifuged at 10,000 g for 5 min. 45µL of the supernatant (incubation of individual 
substrates) or a mixture of TFP incubation supernatant (10 µL) with the supernatants of 
incubation A (45 µL) and B (45µL) were transferred to HPLC vials containing 15 µL 
glafenine (GLF; 5 mg/L) as the internal standard. 
Substrate specificty test 
The specificity of each substrate for its selected enzyme was evaluated by incubating all 
recombinant UGT (rUGT) preparations with each individual probes at the following 
concentrations: ETO (62.5 µM), CDCA (37.5 µM), TFP (100 µM), SER (100 µM), MEF 
(0.5 µM) and AZT (62.5 µM). Experiments were performed in duplicate. 
Enzyme kinetics 
Increasing concentrations of each substrate (10 µM-750 µM for ETO, CDCA, TFP, MEF; 
10 µM-2000 µM for SER and AZT) were incubated both with pooled HLM and its 
selective rUGT, following the procedure described above. Kinetics were model-fitted and 
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kinetic parameters estimated using GraphPad Prism version 5.01. Best-fit models were 
selected among the following: Michaelis-Menten, substrate inhibition and substrate auto-
activation (Hill) models, on the basis of the Akaike Information Criterion. 
Interaction between UGT probes  
Potential interactions between UGT probes were examined by incubating pooled HLM 
with each substrate alone or in combination with each other substrate following the 
general incubation procedure described above (n=2 experiments performed in duplicate).  
LC-MS/MS method 
The 6 substrates and their metabolites were determined in the same 20 min run. The 
chromatographic system consisted of a binary pump (Shimadzu LC-20AD) and an 
autosampler (Shimadzu SIL-20AC) equipped with a 100 µL sample loop. The separation 
was achieved with a Waters Atlantis T3 column (150 x 2.1 mm I.D., particle size 5 µm). 
The mobile phase (flow rate: 200 µL/min) consisted of solution A (0.1 % formic acid in 
HPLC-grade water; v:v) and solution B (0.1% formic acid in methanol; v:v) that formed 
the following gradient: 0-1.5 min (3% B v:v); 1.5-2.5 min (20% B v:v); 2.5-4.5 min (40% 
B v:v); 4.5-5.5 min (70% B v:v); 5.5-10.5 min (90% B v:v); 10.5-16 min (90% B v:v); 
16-16.5 min (3% B v:v); 16.5-20 min (3% B v:v). The column was maintained at 25°C 
and the autosampler at +4°C. 
The detection was performed using an Applied Biosystems 4000 QTRAP™ mass 
spectrometer equipped with a Turbo V Ionspray source and controlled by Analyst® 1.5 
software. Ionization was in the positive mode and acquisition in the Multiple Reaction 
Monitoring (MRM) mode using two transitions for each probe and three for each 
glucuronide. The MRM transitions of the parent probes were selected using infusion of 
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pure compounds (1 mg/L). In the absence of pure compounds, the MRM transitions of 
the glucuronides were based on fragment ions identified when analyzing the incubation 
supernatants using the so-called “enhanced product ion scan mode”. The retention time 
and MRM transitions of the different compounds are given in Table 2. An example of a 
chromatogram is presented in Figure 1. 
All glucuronide concentrations were estimated as molar equivalents with respect to the 
calibration curve of the respective parent probe. Stock solutions of individual substrates 
(1g/L) were prepared in methanol and stored at +4°C. Before each analysis, a solution 
mix of the 6 substrates at 100 mg/L was prepared in the incubation buffer (Tris-HCl 0.1 
M; pH=7.4 containing 10 mM MgCl2). Calibrating standards at 5, 10, 25, 50, 100, 250, 
500, 1000, 2500 and 5000 µg/L were then prepared by cascade dilutions in incubation 
buffer/methanol (56/44% v/v) before each run. After vortex-mixing, 45 µL of each 
standard were transferred to HPLC vials containing 15µL of GLF (5mg/L in methanol) as 
the internal standard. 
Analytical validation 
Intra-assay precision was studied by preparing and analyzing 5 independent replicates of 
quality controls prepared as described above at different concentrations: 40 µg/L, 80 
µg/L, 200 µg/L, 400 µg/L, 800 µg/L, 2,000 µg/L and 4,000 µg/L, on a given day. Inter-
assay precision and linearity were evaluated from the analysis of a calibration set each 
day for 5 days. 
To evaluate the stability of glucuronides after incubation, n=3 incubations of each 
substrate with pooled HLM were performed as described above. One aliquot of 
incubation supernatants was processed immediately after the reaction had been quenched. 
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Two other aliquots of the same supernatants were kept at +4°C for 6h and at -20°C for 24 
h prior to analysis. A fourth aliquot was used to study the stability of the glucuronides 
over three freeze (−20°C)/thaw (room temperature) cycles. Deviations of mean 
glucuronide concentrations in the samples stored at +4°C, -20°C or submitted to 
freeze/thaw cycles from the concentrations measured immediately after incubation were 
used as an indicator of glucuronide stabilities. 
The stability of the glucuronides in the processed samples (auto-sampler stability) was 
assessed over 14h at 4°C. Triplicate incubation samples were analyzed at time 0 and were 
then reinjected after 14h. The mean concentrations of glucuronides after 14h were 
compared to those measured at t=0. 
Statistical analysis. 
Statistical analysis to compare glucuronidation rates obtained using the n-in one strategy 
and individual incubations of each probe, and to evaluate genotype-phenotype 
relationships were carried out using the nonparametric Mann-Whitney and Kruskal-
Wallis tests, respectively. Two-tailed p<0.05 was considered statistically significant. 
Statistical comparisons were performed using GraphPad (version 5.01, San Diego, CA). 
 
 
Results 
Substrate selection 
Candidate probe substrates for UGT 1A1, 1A3, 1A4, 1A6, 1A9, and 2B7 were selected 
based on the literature and their suitability for the LC-MS/MS method (Table 1). Figure 2 
illustrates the results of incubating the selected probes with rUGT 1A1, 1A3, 1A4, 1A6, 
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1A9, 2B7, 2B15 and 2B17. CDCA and TFP were metabolized exclusively by UGT1A3 
and 1A4, respectively. AZT, ETO and MEF were selectively metabolized by their 
respective enzyme (UGT2B7, 1A1, and 1A9, respectively) with minor involvement 
(<10%) of other UGTs (Figure 2).  
The glucuronidation of SER was catalyzed by UGT1A6 and UGT2B17 but the activity of 
UGT1A6 was over fivefold greater than the activity observed with UGT2B17. 
Kinetic experiments with both HLM and rUGT were then performed in order to 
determine the concentration-range of linear metabolism. ETO and MEF showed typical 
Michaelis-Menten kinetics whereas the glucuronidation of CDCA and TFP was best-
fitted by the substrate inhibition equation (Table 1). AZT and SER glucuronidation 
velocity rates were linear up to 2000 µM; higher concentration resulted in low solubility 
or high DMSO concentration (>5%) which precludes kinetic parameter determinations 
for these two substrates. The concentrations of the probes to be used in the assay were 
chosen to be the closest to the apparent Km of the enzyme and to allow the detection of 
the metabolites by LC-MS/MS. 
n-in one procedure development  
Once the selective substrates and their concentrations were chosen as described above, 
this study investigated potential interactions between UGT probes. ETO glucuronidation 
was substantially enhanced by SER (median +21%; [min +17; max +40]) while it tended 
to be decreased by CDCA (-20%; [+2; -34]), AZT (-18%; [-12; -34]) and TFP (-22%; [-2; 
-27]). On the other hand, ETO inhibited CDCA glucuronidation (-23%; [-12; -42]). TFP 
also markedly inhibited the glucuronidation of CDCA (-28% [-31; -17]) and AZT (-42%; 
[-29; -47]) while its own glucuronidation was substantially decreased by CDCA (-31% [-
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25; -41]). No change greater than 15% of control metabolic rates was observed for other 
substrate combinations. We finally retained an n-in one procedure involving three 
separate incubations performed in parallel (A: ETO+MEF; B: CDCA+SER+AZT and 
TFP alone) which were pooled before LC-MS/MS analysis. In order to minimize the 
dilution effect for the glucuronides with the highest analytical quantitation limits, the pool 
consisted of 45% of the supernatants of incubation A and B and 10% of TFP incubation 
supernatant. Five independent experiments consisting of duplicate incubations of the 
substrates, separately or following the n-in one procedure, were performed. In each case, 
there was a close agreement between individual and pooled incubations with insignificant 
differences in velocity rates of 4.3% - 18%, depending on the substrate (Figure 3).  
The relative standard deviation (RSD%) of the results obtained with the n-in one 
procedure, evaluated by phenotyping the same HLM preparation in five independent 
experiments, ranged from 4.3 to 26.7%. 
Analytical validation 
Calibration curves studied using least-square quadratic regression gave excellent 
correlation coefficients for all six compounds (Table 3). The method showed good intra-
assay precisions for all compounds, with mean relative errors (MRE) less than 16.5 % 
and relative standard deviations (RSD) values always less than 16.0 %. Inter-assay 
precision was also good for all compounds over the concentration range, with MRE less 
than 18.9 % and RSD less than 8.6 % (Table 3). 
The glucuronides produced during incubation were found to be stable for at least 6h at 
+4°C and 24h at -20°C to tolerate at least 3 freeze-thaw cycles (Table 4). The processed 
sample stability at +4°C (auto-sampler stability) was demonstrated over 14h. 
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UGT glucuronidation rates in HLM and effect of frequent polymorphisms. 
The n-in one procedure was used to measure glucuronidation enzyme activities in 44 
individual HLM. The sensitivity of the assay was sufficient to accurately determine the 
different UGT activities in all samples. The distribution of UGT1A1, 1A3, 1A4, 1A6, 
1A9 and 2B7 activities are depicted in Figure 4. The UGTs showed different extents of 
variability in activities. Only a two-fold difference was observed between the lowest and 
highest UGT1A9 activity. All other UGTs had higher activity ranges, with 8- to 16-fold 
variation between the minimal and the maximal values. 
We investigated the effect of two frequent genetic polymorphisms in UGT1A1 and 
UGT2B7 on the glucuronidation activities of these two enzymes. The UGT1A1*28 allele 
was associated with a significant decrease in glucuronidation of ETO (p=0.0078) and the 
UGT2B7 -842G>A promoter polymorphism with significantly increased glucuronidation 
of AZT (p=0.0009) (Figure 5). 
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Discussion 
This article describes the development of a n-in one assay for assessing the activity of six 
major human hepatic UGTs in microsomes. The procedure yields similar results to a 
procedure involving individual incubations of UGT probes and allows accurate 
measurement of UGT activities in a bank of 44 genotyped HLM.  
Selective probes for six major human liver UGTs (UGT1A1, 1A3, 1A4, 1A6, 1A9, and 
2B7) were chosen from the literature. Watanabe et al. showed that ETO glucuronidation 
is a specific marker of UGT1A1 using experiments with a panel of recombinant human 
enzymes and inhibition studies with typical UGT substrates in HLM [18]. Similarly, 
UGT1A3 was reported to be specifically responsible for the formation of the major 
metabolite of CDCA (namely CDCA-24-acyl-glucuronide) based on experiments with 
rUGT and correlation analyses between the glucuronidation of CDCA and that of two 
other typical UGT1A3 substrates in HLM [19]. TFP was characterized as a specific probe 
substrate for UGT1A4 using experiments with individual UGTs stably expressed in 
human embryonic kidney (HEK) 293 cells, chemical inhibition experiments with HLM 
and comparative kinetics analysis [5]. Similarly, experiments with HEK293 cells stably 
expressing UGTs showed that AZT is specifically metabolized into 3’-azido-3’-deoxy-5’-
glucuronylthymidine by UGT2B7 [20]. Accordingly, UGT1A1, 1A3, 1A4 and 2B7 were 
the only UGTs of the nine tested here able to conjugate ETO, CDCA, TFP and AZT, 
respectively, confirming that these substrates are excellent markers for these UGTs. 
  We could also confirm the knowledge that SER is a highly selective probe substrate for 
UGT1A6 [21] but the contribution of UGT2B17, although minor, should not be excluded. 
In the case of UGT1A9, we selected MEF instead of propofol (a more commonly used 
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probe for UGT1A9) [15]. Propofol indeed showed unsuitable ionization and 
chromatographic characteristics for the present LC-MS/MS method. MEF has been 
successfully used as a competitive inhibitor of UGT1A9 in different studies [22, 23] and 
the present study demonstrated that it is a selective substrate for UGT1A9, with minor 
contributions of UGT1A1 and UGT1A4. A limitation of this study is that we did not 
include in this assay selective substrates for UGT2B17 (expressed in the human prostate 
but also in the liver), UGT2B4 and more regrettably for UGT2B15. No selective substrate 
has been identified so far for UGT2B17 and apart from its major role in androgen 
metabolism [24], its contribution to drug metabolism remains to be ascertained. 
Similarly, UGT2B4, reported as the most abundant UGT in the liver, appears to exhibit 
low activity towards drugs, and has no selective substrate identified [25]. Its high hepatic 
expression may be due to its crucial role in the glucuronidation of potentially hepatotoxic 
bile acids [10]. In contrast to the two above-mentioned UGTs, UGT2B15 is thought to be 
an important contributor to drug metabolism [25]. Further work needs to be done to 
establish whether S-oxazepam (a probe recently described for this enzyme), can be 
included in the present procedure [26]. It has to be noted that none of the probes selected 
for UGT1A and UGT2B7 were found to be metabolized by UGT2B15. As mentioned 
earlier, UGT2B17 was found to metabolize SER but its activity was approx. 5-time less 
than that observed for the selective enzyme UGT1A6. On the other hand, UGT2B4 was 
found to metabolize MEF with an activity representing 9.4% of the activity of UGT1A9. 
Its activity toward AZT, previously reported by others [27], was not detected here, which 
is presumably explained by the fact that 10-times lower concentrations were used here.  
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Kinetics experiments were performed in order to select the concentrations to be used in 
the assay. In accordance with previous reports, ETO glucuronidation followed the 
classical Michaelis-Menten model [18] and TFP glucuronidation the substrate inhibition 
model [5]. The Km estimated for these pathways were comparable to those previously 
reported using HLM (ETO: Km = 414 vs 440 µM and TFP: Km = 23 vs 61 µM) or 
recombinant enzymes (ETO: Km = 568 vs 503 µM and TFP Km = 106 vs 39 µM). 
UGT1A3-mediated glucuronidation of CDCA was best-fitted by the substrate inhibition 
model whereas Trottier et al. reported Michaelis-Menten kinetics for this pathway [19]. 
The range of CDCA concentration tested here was higher than that used in this previous 
publication (10-750 µM vs 1-250 µM), which probably explain that the authors did not 
observed substrate inhibition. To accommodate for this difference, we finally selected a 
15-µM concentration for the assay, a concentration much lower than the Km we observed 
using HLM (372 µM) or rUGT (130µM) and in the range of those reported by Trottier et 
al. (i.e., 11 µM using HLM and 19 µM using UGT1A3-HEK293 cell lines) [19]. The 
glucuronidation of SER and AZT exhibited unsaturable kinetics over the range of 
substrate concentrations (10-2000 µM) which is consistent with the low affinity 
previously reported for these two substrates (Km = 8800 and 923 µM, respectively) [21, 
28]. The glucuronidation of MEF was best described using the Michalelis-Menten model 
which is only partly in accordance with the literature: Gaganis et al. reported Michaelis-
Menten kinetics using human kidney microsomes and Hill kinetics using rUGT1A9. Also 
the Km estimated here (164 µM using HLM and 11 µM using rUGT1A9) were slightly 
different from those reported by Gaganis et al. (23 µM using human kidney microsomes 
and 449 µM using recombinant UGT1A9). Owing to the high analytical sensitivity for 
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the MEF-glucuronide, we finally retained a concentration of 0.5 µM, much lower than the 
apparent Km of HLM. 
For each substrate, the concentration selected was lower or close to the apparent Km of the 
enzymes (i.e., in a linear range with respect to glucuronide formation rates) and allowed 
accurate determination of metabolite formation rates. Similar conditions were selected in 
the vast majority of P450 or UGT phenotyping assays [29-31], not only to ensure enzyme 
specificities but also to allow for the determination of UGT inhibition profiles. 
Alternatively, the incubation of probes at saturating concentrations has been proposed in 
order to evaluate the total enzyme functional capabilities [31]. Here, we did not evaluate 
functional capabilities of UGT at saturating concentrations. 
Despite the probes being selectively metabolized by their respective enzymes, significant 
interactions were observed when co-incubations were performed. We first observed that 
ETO glucuronidation was increased in presence of SER (approx. + 20%). It has been 
previously shown that UGT1A1-catalyzed estradiol glucuronidation can be stimulated by 
additional UGT1A1 substrates and other compounds [32, 33] through heterotropic 
activation of the enzyme. The same phenomenon presumably occurred here with SER. 
We thus decided to split the two substrates into different incubations. In addition, ETO 
glucuronidation was significantly inhibited by CDCA, TFP and AZT, although none of 
these substrates was metabolized by UGT1A1. A possible explanation for this could be 
that non-competitive inhibition occurred, which has been previously described for this 
enzyme [34]. The mechanism of such inhibition is not fully understood. It is thought to 
involve the binding of the inhibitor at a site away from the substrate binding site. The 
existence of distinct substrate and inhibitor binding sites was also suggested for UGT1A4 
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[35] and UGT2B7 [36] which might explain the inhibition of these UGTs by CDCA and 
TFP, respectively. In this study we did not investigate in much detail the mechanism 
involved in these different interactions because it was far beyond the scope of this study. 
We decided to develop a n-in one strategy. Based on the interactions observed, the six 
substrates were divided into three different incubations (ETO + MEF; CDCA + SER + 
AZT, and TFP alone), the media of which were pooled before analysis. The mean 
difference between the results obtained with the n-in one strategy and individual 
incubations of the different substrates (n=52 experiments) was limited (< 18 %) and was 
likely due to the experimental variability.  
The LC-MS/MS method passed the recommended validation criteria for such analytical 
methods [37]. Two transitions per substrate and three per glucuronide were selected to 
ensure specificity, even for compounds not available as commercial pure products. A 
limitation of our method is that the glucuronides were determined relatively to the 
calibration curves of their respective parent probe. However, this has no consequence on 
the relative comparison of enzyme activities (i.e., comparison of enzyme relative 
activities with and without competitive inhibitor or for a given genotype). 
In order to test the applicability of the method, we assayed 44 individual HLM 
preparations. Glucuronidation activities could be determined in each case, which 
demonstrates that the method is suitable for the determination of UGT activities in the 
range expected with this experimental model. In particular, we were able to accurately 
identify the preparations predicted to have a low or a high activity because of known 
genetic polymorphisms. We observed a gradual decrease of ETO microsomal metabolism 
with the increasing number of UGT1A1*28 allele which is known to decrease UGT1A1 
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expression level and activity [38]. On the other hand, the metabolism of AZT was 
significantly increased by  UGT2B7 -842G>A SNP which was reported to result in a two-
fold increase of UGT2B7 transcription [39] and to affect the in vitro metabolism of at 
least two other UGT2B7 substrates [16, 40].  
In conclusion, the present assay can be used effectively to rapidly assess glucuronidation 
activities of 6 major UGTs in HLM. It offers the potential of being automated on 96-well 
plates to further increase the analytical throughput. This procedure may also be useful for 
the evaluation of UGT activities using other models (hepatocytes, liver slices) as well as 
for the screening of potential UGT inhibitors. 
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Figure 1. LC-MS/MS chromatogram of etoposide (ETO), chenodesoxycholic acid 
(CDCA), trifluoroperazine (TFP), serotonine (SER), mefenamic acid (MEF) and 
azydothymidine (AZT) and their glucuronides after incubation with HLM as described in 
the materials and methods section. 
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Figure 2. Specificity of etoposide (62.5 µM) (A), chenodesoxycholic acid (37.5 µM) (B), 
trifluoroperazine (100 µM) (C), serotonine (100 µM) (D), mefenamic acid (0.5 µM) (E) 
and azydothymidine (62.5µM) (F) for recombinant UDP-glucuronosyl-transferases. 
Activity is expressed as a percentage of the activity obtained for the selective form.  
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Figure 3. Glucuronidation enzyme activities of pool human liver microsomes obtained 
following incubations of UGT probes alone or using the n-in one procedure. Activities 
are means of duplicate incubations performed in 5 independent experiments.  
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Figure 4. Frequency distribution of UDP-glucuronosyltransferase activities measured 
using the n-in one procedure in 44 individual human liver microsomes. 
Activity is expressed in pmole equivalents/min/mg protein. 
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Figure 5. Influence of UGT1A1 TA6/TA7 and UGT2B7 -842G>A polymorphisms on 
etoposide (A) and azydothymidine (B) activities measured using the n-in one procedure 
in 44 individual human liver microsomes (the lines represent the median values). 
p=0.0078 (A); p=0.0009 (B). (One sample remained undetermined for UGT1A1 
genotype). 
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Table 1. UGT probe substrates, concentrations used in the assay and kinetics parameters by human liver microsomes (HLM) and 
recombinant UDP-glucuronosyltransferases (rUGT). 
Enzyme Substrate Reference 
Final 
concentration 
in the assay 
(µM) 
Kinetic parameters 
HLM rUGT 
Vmax 
(µmol eq. min
-1 
mg prot
-1
) 
Km 
(µM) 
Ksi 
(µM) 
Vmax 
(µmol eq. 
min
-1 
mg 
prot
-1
) 
Km 
(µM) 
Ksi 
(µM) 
UGT1A1 Etoposide [18] 25 55 414 - 36 568 - 
UGT1A3 
Chenodesoxycholic 
acid 
[19] 15 17 372 364 8 130 301 
UGT1A4 Trifluoroperazine [5] 40 32 23 3143 4 106 560 
UGT1A6 Serotonin [21] 30 - >2000 - - >2000 - 
UGT1A9 Mefenamic acid [41] 0.5 6 164 - 1 11 - 
UGT2B7 Azidothymidine [20] 70 - >2000 - - >2000 - 
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Table 2. LC-MS/MS transitions and retention times of UGT substrates, their respective 
metabolites and the internal standard (glafenine). 
 
Analyte 
Transition 1 
(m/z) 
Transition 2 
(m/z) 
Transition 3 
(m/z) 
Retention time 
(min) 
Azidothymidine 268→127 268→110  9.7 
Azidothymidine-
glucuronide 
444→268 444→127 444→110 9.3 
Chenodeoxycholic acid 393→357 393→81  16.3 
Chenodeoxycholic acid-
glucuronide 
569→551 569→357 569→313 15.1 
Etoposide 606→209 590→229  10.3 
Etoposide-glucuronide 782→229 782→185 766→185 9.8 
Mefenamic acid 242→180 242→209  14.8 
Mefenamic acid-
glucuronide 
418→242 418→224 418→209 13.1 
Serotonine 177→117 177→77  6.9 
Serotonine-glucuronide 
 
353→177 
353→160 353→117 6.6 
Trifluoperazine 408→141 408→113  10.4 
Trifluoperazine-glucuronide 584→408 584→141 584→113 11.7 
Glafenine 373→281 373→218  9.2 
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Table 3. Inter-assay and intra-assay precision (RSD) and accuracy -mean relative error 
(MRE)- of the LC-MS/MS method. Results are derived from 5 independent experiments. 
 
Substrate 
Concentration 
range (µM) 
Inter-assay Intra-assay 
MRE (%) 
min to 
max 
RSD (%) 
min to 
max 
MRE  
(%) 
min to  
max 
RSD  
(%) 
min to 
max 
Azidothymidine 5→5,000 -8.3/18.9 1.8/7.5 -10.2/12.0 0.5/10.4 
Chenodeoxycholic 
acid 
50→5,000 -8.7/7.1 2.7/8.6 -7.5/10.3 1.2/8.4 
Etoposide 10→5,000 -8.5/17.0 4.1/7.1 -14.3/14.0 1.8/16.0 
Mefenamic acid 25→1,000 -8.9/10.4 2.1/7.1 -14.0/16.5 1.9/4.5 
Serotonine 10→5,000 -10.4/14.6 2.9/6.5 -7.0/11.6 0.7/7.3 
Trifluoperazine 10→1,000 -2.6/18.9 2.6/7.1 -8.6/10.4 1.7/11.8 
 
 34 
Table 4. short-term (6h at +4°C and 24h at -20°C), freeze–thaw and auto-sampler 
stabilities of the glucuronides (Results are derived from n = 3 incubations with pooled 
human liver microsomes). 
 
6h (+4°C) 24h (-20°C) 
freeze–thaw 
cycles 
Auto-sampler 
Mean difference from 
controls (Min, Max) 
-6 % 14% -14% 16% -15% 17% -16% 24% 
 
 
